Search Within

Neuroblastoma Service

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (99)
  2. Meeting Abstract (61)
  3. Review (7)
  4. Book Section (2)
  5. Editorial (1)
Groups
  1. Pediatrics, Department of (170)
  2. Sloan Kettering Institute Postdocs (170)
  3. GSK Faculty (155)
  4. Tow Center for Developmental Oncology (TCDO) (152)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (134)
  6. Center for Molecular Imaging and Biotechnology (96)

More Groups

People
  1. Nai-Kong Cheung (133)
  2. Hong Xu (53)
  3. Hong-Fen Guo (51)
  4. Shakeel Modak (46)
  5. Steven Larson (44)
  6. Stephen Roberts (32)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (22)

More Years

Publications
  1. Journal of Nuclear Medicine (21)
  2. Pediatric Blood and Cancer (17)
  3. Journal of Clinical Oncology (15)
  4. Cancer Research (11)
  5. Journal for ImmunoTherapy of Cancer (7)
  6. Blood (6)

More Publications

Publishers
  1. American Association for Cancer Research (26)
  2. Society of Nuclear Medicine (21)
  3. Wiley Periodicals, Inc (18)
  4. American Society of Clinical Oncology (16)
  5. Biomed Central Ltd (10)
  6. American Society of Hematology (8)

More Publishers

Results (170)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
    Journal Article

    Santich, B. H.; Park, J. A.; Tran, H.; Guo, H. F.; Huse, M.; Cheung, N. K. V.
    Science Translational Medicine (2020)

    Fulltext@MSK | Save
  • An N-acetylgalactosamino dendron-clearing agent for high-therapeutic-index DOTA-hapten pretargeted radioimmunotherapy
    Journal Article

    Cheal, S. M.; Patel, M.; Yang, G.; Veach, D.; Xu, H.; Guo, H. F.; Zanzonico, P. B.; Axworthy, D. B.; Cheung, N. K. V.; Ouerfelli, O.; more...
    Bioconjugate Chemistry (2020)

    Fulltext@MSK | Save
  • Novel alterations in CSF1R, RET, and other diverse kinases in the histiocytoses with biochemical and structural insights into their mechanisms of activation
    Meeting Abstract

    Durham, B.; Lopez-Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S.; Pastore, A.; Mandelker, D.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • PD-L1 checkpoint blockade augments anti-tumor immune response of GD2 or HER2-BsAb ex vivo armed T-cells (EVAT) therapy in osteosarcoma
    Meeting Abstract

    Park, J. A.; Guo, H. F.; Xu, H.; Cheung, N. K. V.
    Blood (2019)

    Fulltext@MSK | Save
  • Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
    Journal Article

    Durham, B. H.; Lopez Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S. X.; Pastore, A.; Yoshimi, A.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Biodistribution and dosimetry of intraventricularly administered (124)I-omburtamab in patients with metastatic leptomeningeal tumors
    Journal Article

    Pandit-Taskar, N.; Zanzonico, P. B.; Kramer, K.; Grkovski, M.; Fung, E. K.; Shi, W.; Zhang, Z.; Lyashchenko, S. K.; Fung, A. M.; Pentlow, K. S.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Silencing Fc domains in T cell-engaging bispecific antibodies improves t-cell trafficking and antitumor potency
    Journal Article

    Wang, L.; Hoseini, S. S.; Xu, H.; Ponomarev, V.; Cheung, N. K.
    Cancer Immunology Research (2019)

    Fulltext@MSK | Save
  • Preliminary tolerability assessment of naxitamab (humanized anti-GD-2 monoclonal antibody) therapy in a phase 2 osteosarcoma trial
    Meeting Abstract

    Dela Cruz, F.; Chou, A.; Roberts, S.; Mauguen, A.; Bonura, J.; Hilliard, J.; Namuduri, M.; Ortiz, M.; Slotkin, E.; Wexler, L.; more...
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor for neuroblastoma: Outpatient treament low immunogenicity, and major responses in a phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for relapsed neuroblastoma resistant to salvage therapy: A phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save